AAAAAA

   
Results: 1-9 |
Results: 9
AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH POOR-RISK MDS AND SECUNDARY AML (SAML)
Authors: DEWITTE T SUCIU S VERHOEF G LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A WIJERMANS P MANDELLI F AMADORI S JEHN U MUUS P DEMUYNCK H DARDENNE M ZITTOUN R WILLEMZE R GRATWOHL A APPERLEY J
Citation: T. Dewitte et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH POOR-RISK MDS AND SECUNDARY AML (SAML), British Journal of Haematology, 102(1), 1998, pp. 282-282
A RANDOMIZED PHASE-II STUDY ON THE EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE COMBINED WITH EITHER AMSACRINE OR IDARUBICIN IN PATIENTS WITH RELAPSEDACUTE-LEUKEMIA - AN EORTC LEUKEMIA COOPERATIVE GROUP PHASE-II STUDY-(06893)
Authors: WILLEMZE R SUCIU S ARCHIMBAUD E MUUS P STRYCKMANS P LOUWAGIE EA BERNEMAN Z TJEAN M WIJERMANS P DOHNER H JEHN U LABAR B JAKSIC B DARDENNE M ZITTOUN R
Citation: R. Willemze et al., A RANDOMIZED PHASE-II STUDY ON THE EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE COMBINED WITH EITHER AMSACRINE OR IDARUBICIN IN PATIENTS WITH RELAPSEDACUTE-LEUKEMIA - AN EORTC LEUKEMIA COOPERATIVE GROUP PHASE-II STUDY-(06893), Leukemia, 11, 1997, pp. 24-27
USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR DURING AND AFTER REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS AGED 61 YEARS AND OLDER WITH ACUTE MYELOID-LEUKEMIA (AML) - FINAL REPORT OF AML-11, A PHASE-III RANDOMIZED STUDY OF THE LEUKEMIA COOPERATIVE GROUP OFANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC-LCG) AND THE DUTCH BELGIAN HEMATOONCOLOGY COOPERATIVE GROUP (HOVON)
Authors: LOWENBERG B SUCIU S ARCHIMBAUD E OSSENKOPPELE G VERHOEF GEG VELLENGA E WIJERMANS P BERNEMAN Z DEKKER AW STRYCKMANS P SCHOUTEN H JEHN U MUUS P SONNEVELD P DARDENNE M ZITTOUN R
Citation: B. Lowenberg et al., USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR DURING AND AFTER REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS AGED 61 YEARS AND OLDER WITH ACUTE MYELOID-LEUKEMIA (AML) - FINAL REPORT OF AML-11, A PHASE-III RANDOMIZED STUDY OF THE LEUKEMIA COOPERATIVE GROUP OFANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC-LCG) AND THE DUTCH BELGIAN HEMATOONCOLOGY COOPERATIVE GROUP (HOVON), Blood, 90(8), 1997, pp. 2952-2961
CYTOGENETIC RESPONSE TO LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE (DAC) IN POOR-RISK MYELODYSPLASTIC SYNDROMES (MDS) - PHASE-II STUDY RESULTS
Authors: LUBBERT M HAAK HL KUNZMANN R DANZERDRIESSEN S VERHOEF G MERTELSMANN R WIJERMANS P
Citation: M. Lubbert et al., CYTOGENETIC RESPONSE TO LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE (DAC) IN POOR-RISK MYELODYSPLASTIC SYNDROMES (MDS) - PHASE-II STUDY RESULTS, Blood, 90(10), 1997, pp. 2591-2591
AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PATIENTS WITH POOR-RISK MDS AND SECONDARY AML (SAML) - A JOINT STUDY OF THE EORTC, EBMT, SAKK AND GIMEMA LEUKEMIA GROUPS
Authors: DEWITTE T SUCIU S VERHOEF G LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A WIJERMANS P MANDELLI F AMADORI S JEHN U MUUS P DEMUYNCK H DARDENNE M ZITTOUN R WILLEMZE R GRATWOHL A APPERLEY J
Citation: T. Dewitte et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PATIENTS WITH POOR-RISK MDS AND SECONDARY AML (SAML) - A JOINT STUDY OF THE EORTC, EBMT, SAKK AND GIMEMA LEUKEMIA GROUPS, Blood, 90(10), 1997, pp. 2594-2594
CLINICAL-EXPERIENCE WITH FLUDARABINE AND ITS IMMUNOSUPPRESSIVE EFFECTS IN PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIAS AND LOW-GRADE LYMPHOMAS
Authors: FENCHEL K BERGMANN L WIJERMANS P ENGERT A PRALLE H MITROU PS DIEHL V HOELZER D
Citation: K. Fenchel et al., CLINICAL-EXPERIENCE WITH FLUDARABINE AND ITS IMMUNOSUPPRESSIVE EFFECTS IN PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIAS AND LOW-GRADE LYMPHOMAS, Leukemia & lymphoma, 18(5-6), 1995, pp. 485-492
GM-CSF DURING AS WELL AS AFTER INDUCTION CHEMOTHERAPY (CT) IN ELDERLYPATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML) - THE EORTC-HOVON PHASE-III TRIAL (AML-11)
Authors: LOWENBERG B SUCIU S ZITTOUN R OSSENKOPPELE G BOOGAERTS MA WIJERMANS P VELLENGA E BERNEMAN Z DEFFER AW SONNEVELD P STRYCKMANS P SOLBU G DARDENNE M DEWITTE T ARCHIMBAUD E
Citation: B. Lowenberg et al., GM-CSF DURING AS WELL AS AFTER INDUCTION CHEMOTHERAPY (CT) IN ELDERLYPATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML) - THE EORTC-HOVON PHASE-III TRIAL (AML-11), Blood, 86(10), 1995, pp. 1719-1719
MYELODYSPLASIA (MDS) AND PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) - IS THERE AN ASSOCIATION
Authors: BOS GMJ HAAK HL GERRITS WBJ WIJERMANS P
Citation: Gmj. Bos et al., MYELODYSPLASIA (MDS) AND PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) - IS THERE AN ASSOCIATION, Blood, 86(10), 1995, pp. 3150-3150
FLUDARABINE IS AN EFFECTIVE AGENT IN IMMUNOCYTIC LYMPHOMA
Authors: FENCHEL K WIJERMANS P MITROU PS HOELZER D BERGMANN L
Citation: K. Fenchel et al., FLUDARABINE IS AN EFFECTIVE AGENT IN IMMUNOCYTIC LYMPHOMA, Onkologie, 17(5), 1994, pp. 508-513
Risultati: 1-9 |